ArticleInterventional radiology (Higashimatsuyama-shi (Japan)2026
Long-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experience.
Article in Interventional radiology (Higashimatsuyama-shi (Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Radiofrequency ablation is a useful alternative to surgery for small renal cell carcinoma in nonsurgical candidates; however, its long-term clinical outcomes remain controversial. This study evaluated the long-term outcomes of radiofrequency ablation in patients with pathologically diagnosed T1a renal cell carcinoma. Material and Methods: This single-center retrospective study included 60 consecutive patients (median age, 67.0 years) who underwent radiofrequency ablation for 62 pathologically diagnosed T1a renal cell carcinomas between 2002 and 2014, all without prior renal cell carcinoma or other active malignancies. Tumor diameters ranged from 1.0 to 3.9 cm (median, 2.3 cm), and 22 (35.5%) renal cell carcinomas were centrally located. Overall and cancer-specific survival, local tumor control, and complications were evaluated. Results: Complete tumor ablation was achieved in 53 renal cell carcinomas (85.5%) after the initial radiofrequency ablation and in all renal cell carcinomas after the second radiofrequency ablation. The local tumor control rates were 96.3% (95% confidence interval, 91.2%-100%) and 91.6% (95% confidence interval, 83.6%-99.6%) at 5 and 10 years, respectively. During a median follow-up period of 9.0 years (range, 1.3-16.5 years), renal cell carcinoma-related death in only one (1.7%) patient. Overall and cancer-specific survival rates were 98.3% (95% confidence interval, 94.9%-100%) and 100% at 5 years, and 85.7% (95% confidence interval, 75.0%-96.4%) and 97.4% (95% confidence interval, 92.5%-100%) at 10 years. Univariate analysis identified diabetes mellitus (p = 0.007) and chronic kidney disease (p = 0.039) as significant prognostic factors. No procedure-related deaths or major complications were observed. Dialysis was initiated in four (6.7%) patients. Conclusions: Radiofrequency ablation is a safe procedure with strong anticancer effects and contributes to the long-term prognosis of patients with T1a renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.